RDMD raises $14M for rare disease real-world evidence generation
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
System1 Biosciences raises $25M in Series A round for neurotherapeutics discovery platform
System1 Biosciences' platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.
Artios raises $84M for developing cancer drugs targeting DNA repair pathway
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
Neurology startup Magnolia Neurosciences raises $31M in Series A round
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.
Therachon raises $60 million in mezzanine financing for rare disease drugs
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.